PainReform reports in vitro test results of PRF-110

PainReform reported in vitro test results comparing the Company’s lead product, PRF-110, versus the industry leader, as a topical analgesia for postoperative pain relief. The in vitro tests were designed to mimic the spreadability attribute critically required for post-surgical topical applications. PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading, including a greater ability to spread evenly due to its viscosity, and superior surface interaction with surgical tissue based on a slide test, which demonstrated sliding of the formulations down inclined, dry and wet surfaces. In phosphate-buffered saline, the sliding of PRF-110 was twice that of the competitor. Ilan Hadar, Chief Executive Officer of PainReform, stated, “We are encouraged by these results, which further demonstrate that PRF-110, our long-acting ropivacaine formulation, provides unique and significant benefits for local administration in postoperative pain management. PRF-110 clearly excelled in terms of surface/tissue spreading and staying in place-a key advantage in achieving effective post-surgical pain relief-as it is critical to have even distribution inside the surgical wound.”